Hormonal
Tirzepatide administration (2.5-15 mg weekly) causes injection-site reactions (ISRs) in 2-8% of patients, presenting as localized erythema, swelling, or pruritus, which are generally mild, self-limiting, and comparable in frequency to other GLP-1 agonists.
Expect mild redness or itching at the injection site in the first few weeks. This is common and usually goes away on its own. Rotate your injection sites (abdomen, thigh, upper arm) and use clean needles to reduce irritation. If you get a rash that spreads or doesn't go away, contact your doctor.
Across the SURPASS clinical trials, injection site reactions with tirzepatide were consistently reported in approximately 2%-6% of patients... In the SURMOUNT obesity trials, ISRs rates were slightly higher, occurring in about 6%-8% of those patients who used tirzepatide for weight management... The reactions were usually mild and resolved on their own within a few days.
Why this rating
Based on large Phase 3 clinical trials (SURPASS, SURMOUNT) and FDA prescribing information.
Source
Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review
Heba Saed El‐Amawy · Anais Brasileiros de Dermatologia · 2025
DOI 10.1016/j.abd.2025.501255
More from this paper
- Tirzepatide use is associated with rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, occurring in approximately 1-4% of patients, often linked to anti-drug antibodies but not always causally related.Good
- Rapid and significant weight loss induced by Tirzepatide leads to aesthetic changes, including facial volume loss ('Ozempic face'), skin laxity, and altered collagen structure, which are secondary to fat loss rather than direct drug toxicity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →